Message from greg pfau on Nov 14 1996 1:09PM EST
I looked thru the IMNX 1995 Annual report. No mention of IL1 alpha or beta.
Only related product they mention is IL1 receptor...Ph I trials for asthma.
Dunno what it all means...waiting to hear on patents...that issue is crucial, in my
mind. Just not enough info to go farther except speculation.
//////////////////////////////////////
Geze...... IMNX has had no active interest in IL-1 for ages. Sorry to let my frustration show, but can't you guys read?
While I'm also interested in the patents, I fail to see why you think that they're "crucial". Isn't it looking as though existing CIST composition of matter claims were sufficient to get in the way of (1) IMNX, who had killed plans for a therapeutic, and (2) PeproTech, an OEM provider of quality cytokines? Seems to me that the business plan could very readily unfold according to a rational plan without additional intellectual property from IMNX. Given that I believe that CIST probably was awarded claims to the ICE-clipped molecule, the IMNX claims may have strengthened any therapeutic hold on IL-1beta (and alpha?). But, while you think this issue is "crucial", do you have any knowledge of ongoing trials with IL-1?? Seems to me that a decent business plan could proceed with the cash award alone, and that the value of any IL-1 patents, beyond reagents, is nebulous at best.
It would be great if the contributors to this thread could focus on what's really happening, rather than speculative BS based on a lack of appreciation for where the biology has already been.
Rick |
